- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| BIODESIX Aktie jetzt für 0€ handeln | |||||
| Do | Biodesix, Inc.: Biodesix to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026 | 1 | GlobeNewswire (USA) | ||
| 06.02. | BIODESIX INC - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 27.01. | Hedge Fund and Insider Trading News: Seth Klarman, Dan Loeb, Michael Burry, Michael Platt, Bridgewater Associates, Greenlight Capital, Biodesix Inc (BDSX), UWM Holdings Corp (UWMC), and More | 4 | Insider Monkey | ||
| 13.01. | Biodesix stock soars as preliminary results exceed guidance, achieves EBITDA profitability | 4 | Investing.com | ||
| 12.01. | Biodesix Surges On Strong Preliminary Q4 And FY2025 Revenue Results | 5 | RTTNews | ||
| 12.01. | Biodesix skyrockets 43%, expects FY revenue to beat guidance | 4 | Seeking Alpha | ||
| 12.01. | Biodesix reports 41% revenue growth in Q4, exceeds 2025 guidance | 3 | Investing.com | ||
| 12.01. | Biodesix, Inc.: Biodesix Announces Preliminary Fourth Quarter and Full-Year 2025 Results (Unaudited) | 162 | GlobeNewswire (Europe) | Estimated Q4 2025 Revenue of $28.8 million, an increase of 41%; Grew full-year revenue to an estimated $88.5 million, an increase of 24%; Affirms guidance of Adjusted EBITDA positivity in Q4 2025.... ► Artikel lesen | |
| 03.12.25 | Biodesix, Inc.: Biodesix to Present New Data at Two Major Upcoming Scientific Meetings | 2 | GlobeNewswire (USA) | ||
| 04.11.25 | Biodesix: Canaccord bestätigt Kaufempfehlung nach starken Q3-Zahlen | 2 | Investing.com Deutsch | ||
| 04.11.25 | Biodesix stock maintains Buy rating at Canaccord after strong Q3 results | 1 | Investing.com | ||
| 04.11.25 | Biodesix raises 2025 revenue guidance to $84M-$86M as primary care expansion accelerates | 4 | Seeking Alpha | ||
| 03.11.25 | Biodesix GAAP EPS of -$1.16 beats by $0.35, revenue of $21.8M beats by $0.82M | 1 | Seeking Alpha | ||
| 03.11.25 | Biodesix, Inc.: Biodesix Announces Third Quarter 2025 Results and Highlights | 132 | GlobeNewswire (Europe) | Q3 2025 Revenue of $21.8 million, an increase of 20% over Q3 2024; Q3 2025 gross profit margin of 81%, a 400-basis point improvement from Q3 2024; Raised FY2025 Total Revenue Guidance to $84-86 million... ► Artikel lesen | |
| 03.11.25 | BIODESIX INC - 10-Q, Quarterly Report | - | SEC Filings | ||
| 03.11.25 | BIODESIX INC - 8-K, Current Report | - | SEC Filings | ||
| 31.10.25 | What's Next: Biodesix's Earnings Preview | 2 | Benzinga.com | ||
| 30.10.25 | Biodesix, Inc.: Biodesix to Share its R&D Roadmap during its Corporate Day Presentation at AMP Annual Meeting | 1 | GlobeNewswire (USA) | ||
| 22.10.25 | Biodesix stock rises after expanded Bio-Rad partnership | 1 | Investing.com | ||
| 22.10.25 | Biodesix to validate ESR1 mutation test for advanced breast cancer | 1 | Investing.com |
1 2 Weiter >>
35 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 42,850 | -0,35 % | Ionos, Kontron, Lanxess, Qiagen, Redcare Pharmacy, Siltronic, TeamViewer: Neue Aktien-Positionen der Short-Seller | Wer Aktien leerverkauft, also auf fallende Kurse spekuliert (Shortselling), unterliegt bestimmten Transparenzpflichten. Aktuelle Meldungen über Leerverkäufe geben Aufschluss darüber. Diese Vorgaben... ► Artikel lesen | |
| VALNEVA | 4,314 | +5,01 % | Valneva auffällig ruhig: Ruhe vor dem Sturm? | ||
| NOVAVAX | 7,013 | -1,09 % | Novavax Licenses Matrix-M Adjuvant To Pfizer For Upfront Payment Of $30 Mln | NEW YORK CITY (dpa-AFX) - Novavax, Inc. (NVAX) announced Tuesday that it has entered into a license agreement with Pfizer, Inc. (PFE) for use of Novavax's Matrix-M adjuvant. Under the terms... ► Artikel lesen | |
| HEIDELBERG PHARMA | 3,050 | +0,33 % | Heidelberg Pharma erhält Meilensteinzahlung von Takeda | Die Heidelberg Pharma AG hat im Rahmen einer bestehenden Lizenzvereinbarung eine Meilensteinzahlung von Takeda erhalten. Die Zahlung wurde mit der Dosierung des ersten Patienten in einer klinischen... ► Artikel lesen | |
| MAINZ BIOMED | 0,751 | 0,00 % | MAINZ BIOMED N.V. - 8-K, Current Report | ||
| INFLARX | 0,703 | +0,72 % | Weekly Buzz: ARS Pharma's Neffy Goes East, SLS Advances, A Signal Of Hope For IFRX? | LONDON (dpa-AFX) - Despite the typical year-end slowdown, the week saw a steady stream of high-impact news, highlighted by global approvals, clinical trial readouts, new product launches, and... ► Artikel lesen | |
| INTELLIA THERAPEUTICS | 9,712 | -0,92 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| TEMPUS AI | 43,000 | +0,47 % | Vorläufige Zahlen überzeugen: Cathie Woods Liebling Tempus AI verzückt Anleger - 100 US-Dollar wieder möglich? | © Foto: SOPA Images - Sipa USATempus AI überrascht mit einem explosiven Wachstum zum Jahresende. Rekordumsätze, ein prall gefüllter Auftragsbestand und eine starke Position im KI-getriebenen Pharmamarkt... ► Artikel lesen | |
| GENMAB | 251,70 | +0,80 % | Genmab A/S: Genmab Announces Net Sales of DARZALEX (daratumumab) for 2025 | Company Announcement Net sales of DARZALEX- in 2025 totaled USD 14,351 millionGenmab receives royalties on worldwide net sales from Johnson & Johnson (J&J, legal entity Janssen Biotech, Inc.) COPENHAGEN... ► Artikel lesen | |
| VIVORYON THERAPEUTICS | 1,406 | +1,88 % | Vivoryon Therapeutics N.V. to Attend and Present in Upcoming Conferences | Vivoryon Therapeutics N.V. to Attend and Present in Upcoming Conferences
Halle (Saale) / Munich, Germany, January 7, 2026 - Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon)... ► Artikel lesen | |
| EDITAS MEDICINE | 1,471 | +4,18 % | Editas Medicine, Inc.: Editas Medicine Nominates EDIT-401, an LDLR-Targeted Medicine, as Lead In Vivo Development Candidate | EDIT-401 achieved ~90% mean LDL-C reduction with single dose in non-human primates EDIT-401 on track for human proof-of-concept data by end of 2026 Strong cash position with operational runway into... ► Artikel lesen | |
| BIOCRYST PHARMACEUTICALS | 5,804 | +1,36 % | BioCryst Pharmaceuticals, Inc.: BioCryst to Present New HAE Data from ORLADEYO (berotralstat) and Navenibart at the 2026 American Academy of Allergy, Asthma & Immunology Annual Meeting | ||
| BIOMARIN PHARMACEUTICAL | 50,56 | 0,00 % | BIOMARIN PHARMACEUTICAL INC - 8-K, Current Report | ||
| EXELIXIS | 35,740 | -0,64 % | Exelixis Reports Solid Earnings-Are New Highs Back on the Table? | ||
| HALOZYME THERAPEUTICS | 64,94 | +0,19 % | Halozyme Therapeutics-Aktie erreicht Rekordhoch von 79,99 USD |
Das Unternehmen BIODESIX INC kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 10,880 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BIODESIX INC finden Sie auf Wallstreet Online.